These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17195761)

  • 1. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
    Pogány K; van Valkengoed IG; Prins JM; Nieuwkerk PT; van der Ende I; Kauffmann RH; Kroon FP; Verbon A; Nievaard MF; Lange JM; Brinkman K
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):395-400. PubMed ID: 17195761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
    Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
    Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
    García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.
    Pialoux G; Quercia RP; Gahery H; Daniel N; Slama L; Girard PM; Bonnard P; Rozenbaum W; Schneider V; Salmon D; Guillet JG
    Clin Vaccine Immunol; 2008 Mar; 15(3):562-8. PubMed ID: 18184824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.
    Porter BO; Anthony KB; Shen J; Hahn B; Keh CE; Maldarelli F; Blackwelder WC; Lane HC; Kovacs JA; Davey RT; Sereti I
    AIDS; 2009 Jan; 23(2):203-12. PubMed ID: 19098490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
    Moltó J; Ruiz L; Romeu J; Martínez-Picado J; Negredo E; Tural C; Sirera G; Clotet B
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1283-8. PubMed ID: 15650419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
    Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
    AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
    Kousignian I; Abgrall S; Duval X; Descamps D; Matheron S; Costagliola D;
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):50-7. PubMed ID: 14501793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
    Waters L; Fisher M; Anderson J; Wood C; Delpech V; Hill T; Walsh J; Orkin C; Bansi L; Gompels M; Phillips A; Johnson M; Gilson R; Easterbrook P; Leen C; Porter K; Gazzard B; Sabin C;
    HIV Med; 2011 May; 12(5):289-98. PubMed ID: 21054749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.